Biocellvia accelerates its R&D in oncology : lung cancer and breast cancer
Biocellvia accelerates its R&D in oncology
mai 23, 2018
Accuracy is a key advantage of our digital image analysis program
Accuracy is a key advantage of our digital image analysis programs
juillet 5, 2018
Show all

Biocellvia Gears Up For NASH !

Biocellvia gears up for NASH

Today marks the first International NASH Day, to raise awareness for this disease and hopefully accelerates the discovery and development of better treatment solutions for millions of patients suffering from this debilitating condition. This groundbreaking event aims to motivate the public to learn more about this silent killer called NASH.

Biocellvia is a French startup which creates fully automated digital image analysis programs in order to help biotechs and big pharmas in the drug discovery process at the preclinical stage. This startup first began developing customized programs for respiratory diseases. Now, by leveraging their decades of expertise and experience, Biocellvia’s CEO and CSO decided to focus their resources to tackle this liver disease with an enormous unmet medical need, affecting large populations around the world.

Research and Development Dedicated to NASH

Biocellvia’s Research & Development team has been focusing on NASH for the last 10 months. Our aim was to create a completely automated digital image analysis program in order to evaluate the efficacy of lead molecules against NASH and the level of disease severity by assessing different parameters.

This unique program will help research teams in biotechs and big pharmas obtain robust, quantitative, and allow them to better interpret their study results and make critical decisions on their compound candidates.

Public Health Interest

In recent years, NASH has quickly become a very serious public health issue. Experts estimate that this liver disorder affects approximately 20 percent of the U.S. population, and want to urge primary-care providers to send patients for testing earlier in diagnosis. Called nonalcoholic steatohepatitis, or NASH for short, it does not result from drug use, alcoholism, sexual contact, water contaminants or viruses. Rather, this particular liver condition occurs when too much fat is stored in liver cells. Currently, there is no approved therapies to cure patients inflicted by NASH.

Biocellvia is making an important contribution to tackle this grave public health challenge, by using its proprietary technology to support scientists to make better informed decisions to develop effective, affordable drugs for patients. By incorporating Biocellvia’s digital technology in their drug development process, pharmaceutical companies can drastically reduce the time and cost in their R&D process, because Biocellvia’s specialized programs can perform image analysis in a matter of hours, whereas traditionally the same manual work takes weeks or months.

To learn more about Biocellvia’s NASH digital automated programs, contact us.

I have a background as a researcher academic with more than 30 years of age experience. Professor at the "Mayo Clinic " (USA), I created the company Biocellvia in 2011 with my son Olivier Julé. During the creation of the box, I perceived the power of digital image analysis in the framework of the research, and the interest that they cause.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

We are working hard on our new website!
Unfortunately, we haven't yet found a technology as fast as Biocellvia's .
Please be kind to our old design and come say hello to the new one when it is up and running.